• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

immunology

Uptal Patel
Biotech

Biogen returns to its roots with a West Coast immunology outpost

Biogen used last year's HI-Bio buy as a chance to reestablish itself on the West Coast and return to the science that sparked its founding.
Darren Incorvaia Nov 18, 2025 12:25pm
Glowing puzzle piece fitting into puzzle

Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist

Oct 24, 2025 9:15am
human brain abstract art

Nilo launches with $101M and mission to harness neural circuits

Oct 8, 2025 9:55am
AZ

AstraZeneca, Algen Biotechnologies pen $555M AI pact

Oct 6, 2025 8:00am
Sanofi

Sanofi's R&D chief 'pretty pragmatic' about clinical setbacks

Sep 17, 2025 8:01am
acquisition merger arrows

AbbVie ends development of IL-1 asset in ulcerative colitis

Jul 31, 2025 12:32pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings